XML 18 R7.htm IDEA: XBRL DOCUMENT v3.21.1
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment
Preferred Stock
Common Stock
Additional Paid-In Capital
Retained Earnings
Retained Earnings
Cumulative Effect, Period of Adoption, Adjustment
Accumulated Other Comprehensive Loss
Beginning balance at Dec. 31, 2019 $ 2,476,310 $ (5,077) $ 0 $ 26,639 $ 1,108,649 $ 2,177,513 $ (5,077) $ (836,491)
Beginning balance (in shares) at Dec. 31, 2019       53,278,316        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Comprehensive income (loss) (188,067)         (109,613)   (78,454)
Common stock dividends declared (30,379)         (30,379)    
Common stock issued under employee stock award and stock purchase plans (in shares) [1],[2]       760,746        
Common stock issued under employee stock award and stock purchase plans [1],[2] (1,218)     $ 380 (1,598)      
Common stock repurchases (in shares)       (303,098)        
Common stock repurchases (11,924)     $ (152) (6,214) (5,558)    
Share-based compensation 3,091       3,091      
Ending balance at Mar. 31, 2020 2,242,736   0 $ 26,867 1,103,928 2,026,886   (914,945)
Ending balance (in shares) at Mar. 31, 2020       53,735,964        
Beginning balance at Dec. 31, 2020 $ 2,255,557   0 $ 26,866 1,132,954 1,912,942   (817,205)
Beginning balance (in shares) at Dec. 31, 2020 53,732,033     53,732,033        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Comprehensive income (loss) $ 65,263         50,825   14,438
Common stock dividends declared (30,569)         (30,569)    
Common stock issued under employee stock award and stock purchase plans (in shares) [1],[2]       426,311        
Common stock issued under employee stock award and stock purchase plans [1],[2] (1,797)     $ 213 (2,010)      
Common stock repurchases (in shares)       (287,957)        
Common stock repurchases (19,444)     $ (144) (5,977) (13,323)    
Share-based compensation 10,677       10,677      
Ending balance at Mar. 31, 2021 $ 2,279,687   $ 0 $ 26,935 $ 1,135,644 $ 1,919,875   $ (802,767)
Ending balance (in shares) at Mar. 31, 2021 53,870,387     53,870,387        
[1] Net of common shares delivered as payment for the exercise price or to satisfy the holders’ withholding tax liability upon exercise of options.
[2] Represents open-market transactions of common shares by the trustee of our deferred compensation plans.